Compare Appian Corp (APPN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs ResMed Inc. — how do they compare? Appian Corp trades at $35.5 (market cap $2.54B), while ResMed Inc. trades at $220.4 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 12.8× Appian Corp's market cap, and ResMed Inc. pays a 1.17% dividend while Appian Corp pays none. Which is the better fit depends on your goals.
| APPN | RMD | |
|---|---|---|
Market Cap | $2.54B | $32.61B |
Sector | Technology | Health |
52-Week High | $45.64 | $293.73 |
52-Week Low | $18.72 | $182.82 |
Enterprise Value | $2.67B | $31.97B |
Dividend Yield | — | 1.17% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
